Cargando…

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report

BACKGROUND: The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of next-generation sequencing, uncommon epidermal growth factor receptor mutations are more...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Acker, Lander, Stevens, Dieter, Vermaelen, Karim, Surmont, Veerle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609878/ https://www.ncbi.nlm.nih.gov/pubmed/34809713 http://dx.doi.org/10.1186/s13256-021-02994-0

Ejemplares similares

A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review
por: Wei, Yu, et al.
Publicado: (2021)

Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report
por: An, Ning, et al.
Publicado: (2019)

Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report
por: Xu, Fei, et al.
Publicado: (2022)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
por: Ma, Chunhua, et al.
Publicado: (2020)

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Investigational Approaches for Mesothelioma
por: Surmont, Veerle F., et al.
Publicado: (2011)

Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
por: Kunishige, Michihiro, et al.
Publicado: (2022)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
por: Ma, Chunhua, et al.
Publicado: (2020)

Ubuntu 7.10 Linux: Unleashed
por: Hudson, Andrew, et al.
Publicado: (2008)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
por: Cortiula, Francesco, et al.
Publicado: (2022)

Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
por: Yu, Nian, et al.
Publicado: (2021)

Sistema procesador de datos IBM/709

Unloading at Cointrin Airport of the IBM 709 computer
por: CERN PhotoLab
Publicado: (1960)

Reference manual 709 Data Processing system
por: International Business Machines. New York
Publicado: (1959)

B709 Mitochondrial Control of Cell Death
por: Kroemer, Guido
Publicado: (2001)

Get Through FRCA Primary – 710 MCQ's
por: Mirakhur, Rajinder K
Publicado: (2006)

Die elektronische Rechenanlage IBM 709 im CERN
Publicado: (1961)

Reference manual 709/7090 Fortran programming system
por: International Business Machines. New York
Publicado: (1958)

BIRICODAR (VX-710; Incel™): an effective chemosensitizer in neuroblastoma
por: Yanagisawa, T, et al.
Publicado: (1999)

Off-line production of intense $^{7,10}Be^{+}$ beams
por: Köster, U, et al.
Publicado: (2002)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
por: Nishiya, Naoyuki, et al.
Publicado: (2019)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan
por: Graham, Jonathan, et al.
Publicado: (2018)

Draft Genome Sequence of Necropsobacter rosorum Strain P709(T)
por: Padmanabhan, Roshan, et al.
Publicado: (2014)

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
por: Tamura, Tomoki, et al.
Publicado: (2021)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
por: Wu, Jenn-Yu, et al.
Publicado: (2016)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fe7jovunu5u5cmv8lsenpkkvk8